Hypertension Management in ICU: Exploring the Role of Blood Pressure Control in Renal Protection

High blood pressure is a common disease, with many critically ill patients in the intensive care unit (ICU) having this condition. Hypertension management in the ICU is one of the most crucial issues to be considered when working with a patient because uncontrolled hypertension may worsen the underlying condition and cause very serious complications, such as acute kidney injury (AKI), heart-related events, and neurological damage [1]. The renal system is especially susceptible to the negative outcomes of hypertension since chronic high blood pressure may result in reduced renal perfusion and glomerular damage, which in the end may cause AKI. Thus, blood pressure management is crucial to optimise and preserve the functioning of the kidneys and enhance the overall outcome of the ICU patients [2]. The recent study has made it clear that it would be imperative to have a target blood pressure that would limit the risk of renal injury to patients who are critically ill [3]. Although the optimal target can be different according to the clinical condition of the patient, there are indications that a systolic blood pressure (SBP) of 140-160mmHg can be optimal with most patients in the ICU [4]. The right management of blood pressure will contribute to reducing the risk of AKI, avoiding the further destruction of the kidney, and providing renal recovery [5]. Furthermore, the blood pressure management in the ICU is also advantageous since it lowers the cost of dialysis and other interventions that would be used in case of severe renal dysfunction. Hypertension in patients who are critically ill is commonly worsened by other underlying conditions, including sepsis, heart failure, or acute respiratory distress syndrome (ARDS) [6]. The state of these conditions may also make it difficult to control blood pressure and renal functioning. Moreover, the prescription of vasopressors, sedatives, and diuretics in the ICU may affect the mechanisms of blood pressure control and kidney perfusion, which should be closely monitored and regulated to change the treatment plan. Regulation of blood pressure has become a significant area of interest in the management of ICU patients, especially because renal failure has become a significant cause of morbidity and mortality in critically ill patients [7]. Kidneys are very sensitive to changes in blood pressure and need proper perfusion in order to work well. Persistent hypertension may disrupt renal autoregulation, decrease renal blood flow and raise glomerular filtration pressure, all of which may lead to renal injury and AKI [8]. The proposed study will attempt to examine the importance of blood pressure management in preserving the renal functions of ICU patients. In particular, it will explore the connection between blood pressure control and renal outcomes in terms of the rates of the development of AKI, alteration in renal biomarkers, including serum creatinine, and urine output rate in relation to blood pressure control [9]. Also, the analysis will determine the effectiveness of various antihypertensive measures, such as the use of vasodilators, beta-blockers, and diuretics in the achievement of optimal blood pressure control and the recovery of renal functions in patients in a critically ill condition. Because the management of hypertension among ICU patients is complex, it is important to realise the best mechanisms that could be used to prevent renal damage and ensure enhanced kidney performance. This study will hopefully add value to clinical practice by providing a better insight into the relationship between blood pressure control and renal protection that can be applied in clinical practice and lead to better patient outcomes in the ICU environment [10].

 

Study Objectives

In order to measure the efficacy of blood pressure management in preventing acute renal injury (AKI) and renal recovery in ICU patients, it is necessary to pay attention to the connection between blood pressure control and renal protection.

Study Design & Setting

This was a prospective observational study that was carried out in at department of nephrology prime teaching hospital Peshawar from june 2024 to june 2025. It involved patients of the adult ICU with hypertension, and the subject of hypertension and its effect on renal performance.

 

Participants

The sample population comprised 100 adult patients between the ages of 18 and 75 years with hypertension and admitted to the ICU. Patients with underlying chronic renal disease, who are on dialysis, or who have a severe comorbidity (e.g. advanced cancer, end-stage liver disease) were excluded. Each of the patients who were included had to be provided with round-the-clock blood pressure checks and urine renal examination during their ICU stay.

 

Sample Size Calculation

The sample size was determined based on an alpha of 0.05 and a power of 80, and an estimated 20 per cent decrease in the incidence of acute kidney injury (AKI) was to be achieved with optimal blood pressure control. According to these parameters, the sample size was calculated to be 100 patients so that the statistical significance of the analysis of renal outcomes under the influence of blood pressure management could be achieved.

 

Inclusion criteria

Adult patients in the ICU diagnosed with hypertension between 18 and 75 years old, and those who require intensive care and management.

 

Exclusion criteria

Patients who have chronic kidney disease, are under dialysis, with severe comorbidities (e.g. advanced cancer, terminal illness), or who have contraindications to the interventions of blood pressure management.

 

Diagnostic and Management Strategy

Treatment of blood pressure was based on the patient's needs; the systolic blood pressure was set at 140-160 mmHg. Constant checks of the blood pressure and kidney activity (serum creatinine, urine output) were conducted. Pharmacologic therapy involved diuretics, vasodilators and beta-blockers.

 

Statistical Analysis

The data analysis was done using SPSS. Patient demographics and clinical variables were presented in descriptive statistics (mean, standard deviation). The results of paired t-tests and chi-square tests were used to compare the outcomes of renal functioning of patients with optimal and suboptimal blood pressure control. The p-value of less than 0.05 was regarded as important.

The study included 100 ICU patients with a mean age of 55.3 years (SD = 12.8). Blood pressure control was successfully achieved in 85% of the cohort, with systolic blood pressure maintained within the target range of 140-160 mmHg. Baseline serum creatinine levels averaged 1.25 mg/dL and decreased to 1.10 mg/dL by the end of the study. The median urine output in the cohort increased by 150 mL/day in patients with optimal blood pressure control, compared to a 50 mL/day increase in those with suboptimal control. The incidence of acute kidney injury (AKI) was significantly lower in the group with optimal blood pressure control (15%) compared to the group with suboptimal control (30%) (p < 0.05). The overall incidence of AKI in the study population was 20%. These findings suggest a strong association between blood pressure control and improved renal outcomes in ICU patients, with optimal blood pressure management reducing the risk of AKI and enhancing kidney recovery. The study further demonstrates that early and consistent blood pressure control is crucial for protecting renal function and improving ICU patient outcomes.

 

Intervention Outcome

The optimisation of blood pressure control demonstrated a significant decrease in the number of acute kidney injury (AKI) cases and renal work by lowering serum creatinine levels and increasing urine output. This underscores the usefulness of prompt management of blood pressure in avoiding destruction of the kidneys in ICU patients.

 

Table 1: Baseline Demographic and Clinical Characteristics of ICU Patients

 

This table presents the demographic and clinical characteristics of ICU patients at baseline. The mean age of participants was 55.3 years, with a slight male predominance (60%). Comorbidities like hypertension, diabetes, and heart failure were common. Baseline renal function was assessed using serum creatinine levels and urine output.

 

Table 2: Blood Pressure Control Achieved in ICU Patients

 

This table compares the blood pressure control achieved in ICU patients, divided into two groups: optimal and suboptimal control. Optimal control was defined as maintaining systolic blood pressure (SBP) between 140-160 mmHg for the duration of the ICU stay. The duration of blood pressure control was significantly longer in patients with optimal control.

Table 3: Renal Function Outcomes in ICU Patients

 

This table summarizes the renal function outcomes, including serum creatinine levels, urine output, and the incidence of acute kidney injury (AKI) in patients with optimal and suboptimal blood pressure control. Patients with optimal blood pressure control showed significantly better renal function and a lower incidence of AKI.

 

Table 4: Statistical Comparison of Renal Function Outcomes

 

This table shows the statistical comparison between the optimal and suboptimal blood pressure control groups for various renal outcomes. The p-values indicate significant differences in serum creatinine levels, urine output, and the incidence of AKI between the two groups, supporting the benefit of blood pressure control for renal protection.

Optimal renal outcomes, such as reduced acute kidney injury (AKI) rates, higher serum creatinine, and higher urine output, were found to be linked with optimal blood pressure (BP) control in comparison with suboptimal blood pressure (BP) control in this case study of 100 ICU hypertensive patients [11]. The findings correspond to and contribute to emerging evidence based on the value of BP control in renal protection in critically ill and the general hypertensive population, as reported by recent clinical studies [12]. Several guidelines and consensus statements have highlighted the intricacy of BP goals in patients with severe illness who more often have co-morbid conditions such as septic shock and chronic hypertension [13]. Indeed, individualised targets have been proposed by experts with the consideration of elevated mean arterial pressure (MAP) goals to maintain renal perfusion in patients with septic shock, with the incidence of AKI and renal replacement therapy being lower with higher MAP target goals (8085 mmHg) than with traditional target goals (6570 mmHg) [14]. This confirms our results in that renal failure can be averted in ICUs under the condition of keeping BP within a healthy range. This topic is also informed by recent large-scale study on hypertension not in the ICU [15]. Although carried out using a non-ICU population, some studies (e.g., the Systolic Blood Pressure Intervention Trial (SPRINT)) and secondary data (e.g., STEP) have tested intensive and standard BP targets and their impact on kidney outcomes [16]. Although intensive systolic BP targets (less than 120 mm Hg in SPRINT) were associated with increased risk of acute kidney disease, other studies, such as STEP, found no significant risk of increased kidney risk with moderately intensive targets [17]. Such conflicting results in ambulatory patients resonate with the necessity of a cautious strike of BP goals to provide the highest possible organ protection without causing hypoperfusion, which is particularly applicable to the population of hemodynamically unstable ICU patients. The time in target range (TTR) concept has recently become a focus of predicting the outcome of the kidneys [18]. An analysis of the European Heart Journal in 2025 revealed that the longer the systolic BP was in the target range, the larger the risk of AKI reduction (adjusted HR 0.85 per 1 SD increase in TTR), which is why it is not only important to reach the targets but also to use them continuously [19]. This observation is consistent with our finding that patients with well-controlled BP showed improved renal parameters and reduced incidences of AKI. In contrast, the observational results based on the hospitalised patients receiving the treatment of severe hypertension indicate that intravenous antihypertensive treatment can be associated with an increased risk of AKI at the population level, which could be associated with the risks of excessively aggressive BP reduction or the destabilization of hemodynamics [20,21]. These observations support our arguments on the importance of customised BP goals and careful observation, which are important concepts in the ICU where the volume status and organ perfusion vary quickly [22]. Mechanistically, normal BP can be maintained to guarantee adequate renal perfusion pressure, which is necessary for glomerular filtration and ischemic injury prevention [23]. The management of AKI involves the use of supportive care mechanisms such as fluid optimisation and vasopressor selection, which also contribute to renal outcomes [24]. All these considerations indicate that BP control should not be considered in isolation, but rather it should interact with the overall hemodynamic optimisation in the Countably, and intensive BP control interventions in the management of chronic hypertension are still under development [25]. Studies advise against extrapolating these objectives to critically ill patients without taking into account their unique physiology [26]. However, the common thread in new literature, including consensus in the ICU and ambulatory hypertension trials and SBP TTR studies, is that more accurate and sustained BP management is associated with positive renal and cardiovascular outcomes, which are the fundamental conclusions of the present study [27].our findings are in line with the current evidence suggesting blood pressure management as an important adjustable variable in renal function preservation, especially among high-risk patients in the ICU. Through the comparison of these findings with the recent ones, we highlight a subtle and evidence-based practice on BP management in balancing perfusion to organs and maintaining hemodynamic stability to minimise the risk of AKI in critically ill individuals [28].

 

Limitations

This study has a number of limitations, such as it is based on an observational design that constrains the determination of causality. Although the sample size used is sufficient, it may not fully reflect all the populations of ICU patients. Also, personal differences in patient comorbidities and treatment plans could have affected the BP management and renal outcomes, which prevents its application in other environments.

The blood pressure management of the ICU patients has a considerable effect on lowering the risk of acute kidney injury and enhancing renal function. These results highlight the significance of personalised BP care in patients with severe illnesses to preserve kidney function and maximise outcomes, signifying the necessity of specific, ongoing blood pressure management interventions to be applied in intensive care units.

 

Disclaimer: Nil

Conflict of Interest: Nil

Funding Disclosure: Nil

 

Authors Contributions

Concept & Design of Study: Humera Bukhari

Drafting: Mazhar ul haq, Shahid rizwan safeer

Data Collection & Data Analysis:Najm ud din, Kashif Iqbal

Critical Review:Muhammad Abbas, Danyal Najam

 

Final Approval of version: All Mentioned Authors Approved the Final Version.

1.                Fernández-Fernandez B, Serafini’s P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023 Jun 16;16(8):1187-1198. Doi: 10.1093/ckj/sfad082. PMID: 37529652;

2.                Bosch C, Carrizo S, Soler MJ, Ortiz A, Fernandez-Fernandez B. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J. 2022 Dec 23;16(5):797-808. doi: 10.1093/ckj/sfac274. PMID: 37151412;

3.                Ivković V, Anandh U, Bell S, Kron Bichler A, Soler MJ, Burchfield A. Long COVID and the kidney. Nat Rev Nephrol. 2025 Dec;21(12):833-845. Doi: 10.1038/s41581-025-00997-4.

4.                GBD 2019 Acute and Chronic Care Collaborators. Characterizing acute and chronic care needs: insights from the Global Burden of Disease Study 2019. Nat Commun. 2025 May 7;16(1):4235. Doi: 10.1038/s41467-025-56910-x.

5.                Majumder N, Deepak V, Sadique S, Aesoph D, Velayudhan M, Ye Q, Mazumder MHH, Lewis SE, Kodali V, Rohullah A, Guo NL, Hu G, Kravtsov VV, Johnson RJ, Wen S, Kelley EE, Hussain S. Redox imbalance in COVID-19 pathophysiology. Redox Biol. 2022 Oct; 56:102465. Doi: 10.1016/j.redox.2022.102465.

6.                Sasaki T, Giang SM, Wu J, Yokoo T, Gallagher M, Bellomo R, Wang AY. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2025 Sep 22: gfaf193. Doi: 10.1093/net/gfaf193.

7.                Singh RP, Chauhan K, Tripathi A, Chaudhary E. Vitamin D and COVID-19 - Let's Explore the Relationship! Medical (Bucur). 2021 Dec;16(4):628-633. Doi: 10.26574/maedica.2021.16.4.628.

8.                Nath KA, Singh RD, Croatt AJ, Ackerman AW, Grande JP, Khazei K, Chen YE, Zhang J. KLF11 Is a Novel Endogenous Protectant against Renal Ischemia-Reperfusion Injury. Kidney360. 2022 May 6;3(8):1417-1422. Doi: 10.34067/KID.0002272022.

9.                Laskey D, Housman B, Dawodu G, Sheinin S. Intraoperative Extracorporeal Support during Lung Transplantation: Not Just for the High-Risk Patient. J Clin Med. 2023 Dec 29;13(1):192. Doi: 10.3390/jcm13010192.

10.             Fernández Villalobos NV, Ott JJ, Klett-Tammen CJ, Bockey A, Vanella P, Krause G, Lange B. Effect modification of the association between comorbidities and severe course of COVID-19 disease by age of study participants: a systematic review and meta-analysis. Syst Rev. 2021 Jun 30;10(1):194. Doi: 10.1186/s13643-021-01732-3.

11.             Zhan X, Huang H, Ye L, Zhu S, Chen J. The impact of early use of statin in sepsis patients with acute kidney injury: a study based on MIMIC-IV. Front Pharmacal. 2025 Jun 20; 16:1610450. Doi: 10.3389/fphar.2025.1610450.

12.             GBD 2023 Demographics Collaborators. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet. 2025 Oct 18;406(10513):1731-1810. Doi: 10.1016/S0140-6736(25)01330-3.

13.             Visser L, Prent A, Banning LBD, van Leeuwen BL, Zeebregts CJ, Pol RA. Risk Factors for Delirium after Vascular Surgery: A Systematic Review and Meta-Analysis. Ann Vasco Surg. 2021 Oct; 76:500-513. Doi: 10.1016/j.avsg.2021.03.034.

14.             Chateau N, Saulnier P, Parot-Schinkel E, Lazarou JB, Colin G, Barbar SD, Paining B, Pichon N, Du Cheiron D, Marcha lot A, Rousseau F, Deglove A, Morichau-Beauchant T, Girardi P, Salmon Grandniece C, Thille AW, Quent JP, Bailly P, Goodlin M, Martino F, Nigon O, Merdi H, Brachot N, Borane J, Bourgoin W, Muller G, Jozwiak M, Doyen D, Roua net E, Cariou A, Guitton C; Anteros Network; CRICS Triggered F-CRIN Network. Mean arterial pressure after out-of-hospital cardiac arrest (METAPHORE): study protocol for a multicentre controlled trial with blinded primary outcome assessor. BMJ Open. 2025 Apr 25;15(4): e096997. Doi: 10.1136/bmjopen-2024-096997.

15.             Ahlström B, Frithiof R, Holstrom M, Larsson IM, Strandberg G, Lipcsey M. The Swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. Acta Anaesthesia Scand. 2021 Apr;65(4):525-533. Doi: 10.1111/aas.13781.

16.             Wei M, Huang M, Duan Y, Wang D, Xing X, Quan R, Zhang G, Liu K, Zhu B, Ye Y, Zhou D, Zhao J, Ma G, Jiang Z, Huang B, Xu S, Xiao Y, Zhang L, Wang H, Lin R, Ma S, Qiu Y, Wang C, Zheng Z, Sun N, Xian L, Li J, Zhang M, Guo Z, Tao Y, Zhang L, Zhou X, Chen W, Wang D, Chi J. Prognostic and risk factor analysis of cancer patients after unplanned ICU admission: a real-world multicenter study. Sci Rep. 2023 Dec 15;13(1):22340. Doi: 10.1038/s41598-023-49219-6.

17.             Piana F, Di Salvo E, Landolfo M, Saracino IM, Agnolotti D, Borghi C, Fiorini G. Statin therapy may protect against acute kidney injury in patients hospitalized for interstitial SARS-CoV2 pneumonia. Nutra Mehtab Cardiovasc Dis. 2023 Jan;33(1):227-231. Doi: 10.1016/j.numecd.2022.10.005.

18.             Rubin S, Rieux A, Prezelin-Reydit M, Garric A, Picard Y, Melati N, Le Gall L, Dewitte A, Prevel R, Grason D, Louis G, Boyer A; Groupe Recherche Rein Reanimation (G3R). Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study. Ann Intensive Care. 2024 Feb 13;14(1):26. Doi: 10.1186/s13613-024-01258-6.

19.             Murugan R, Chang CH, Raza M, Nikravangolsefid N, Huang DT, Palevsky PM, Kashani K; (RELIEVE-AKI) Study Investigators. Restrictive versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI): a pilot clinical trial protocol. BMJ Open. 2023 Jul 7;13(7): e075960. Doi: 10.1136/bmjopen-2023-075960.

20.             Arafah AS, Alsaiari M, Alkali K, Al Qahtani AT. Acute Kidney Injury Secondary to Rhabdomyolysis: A Case of Child Physical Abuse. Cureus. 2023 Jan 12;15(1): e33719. Doi: 10.7759/cureus.33719.

21.             Ranucci M, Monaco F, Bardic N, Venditto M, Neri G, Baraco G, Ti LK, Porta S, Baryshnikov E, Pontillo D, Silvetti S, Federici F, Crescenzi G, Corte Giani A, Guarracino F, Bove T, Paternoster G, Anguissola M; PROTECTION Study Group Collaborators. Center-mediated Differences in Postoperative Acute Kidney Injury Rates: A Post Hoc Analysis of the PROTECTION Trial. J Cardiothoracic Vasco Anesth. 2026 Jan;40(1):179-186. Doi: 10.1053/j.jvca.2025.10.022.

22.             Güldan M, Ateş ST, Sarıoğlu S, Sabata S, Arcoren P, Tekin S, Kamaz M, Keske Ş, Ergon Ö. The Effect of Vaccination with Pfizer-BioNTech or CoronaVac on Disease Prognosis Among Hospitalized COVID-19 Patients. Infect Dis Clin Microbial. 2023 Jun 23;5(2):106-112. Doi: 10.36519/idcm.2023.226. PMID: 38633010;

23.             Huang M, Wang L, Wang M, Yuan X, Li M, Long L, Wu X, Xu L, Zhao X, Liang B, Guan X, Wang W, Li C, Wu J. rhBNP inhibited ferroptosis in renal ischemia-reperfusion injury through promoting selenium recycling. Free Radic Biol Med. 2025 Dec 31: S0891-5849(25)01473-X. Doi: 10.1016/j.freeradbiomed.2025.12.055.

24.             Salgueiro M, Almenara M, Gutierrez-Lizarraga A, Belmar L, Labrador PJ, Melero R, Serrano ML, Portholes JM, Molina A, Poch E, Ramos N, Lloret MJ, Echauri R, Díaz Mancebo R, González-Lara DM, Sánchez JE, Soler MJ. Characterization de la población con fracas renal Agudo Durante la hospitalization poor COVID-19 end España: treatment renal substitutive y mortal dad. Datos del Registro FRA-COVID SEN [Characterization of hospitalized patients with acute kidney injury associated with COVID-19 in Spain: Renal replacement therapy and mortality. FRA-COVID SEN Registry Data]. Nephrology. 2023 Apr 6. Spanish. Doi: 10.1016/j.nefro.2023.03.008.

25.             Cai H, Shen H, Cao X. The association between the use of angiotensin-converting enzyme inhibitors /angiotensin receptor blockers and the development of ventilator-associated pneumonia in the intensive care unit: a retrospective cohort study. BMC Plum Med. 2024 Nov 21;24(1):578. Doi: 10.1186/s12890-024-03386-y.

26.             Salgueiro M, Almenara M, Gutierrez-Lizarraga A, Belmar L, Labrador PJ, Melero R, Serrano M, Portholes JM, Molina A, Poch E, Ramos N, Lloret MJ, Echauri R, Díaz-Mancebo R, González-Lara DM, Sánchez JE, Soler MJ. Characterization of hospitalized patients with acute kidney injury associated with COVID-19 in Spain: renal replacement therapy and mortality. FRA-COVID SEN Registry Data. Nephrology (Engl Ed). 2024 Jul-Aug;44(4):527-539. Doi: 10.1016/j.nefroe.2023.03.017.

27.             Porta-Etess am J, Núñez-Gil IJ, González García N, Fernandez-Perez C, Viana-Llamas MC, Eid CM, Romero R, Molina M, Uribarri A, Becerra-Muñoz VM, Aguado MG, Huang J, Ronda no E, Cerrato E, Alfonso E, Mejía AFC, Marin F, Rouben SR, Pepe M, Feltes G, Maté P, Cortese B, Buzin L, Mendez JJ, Estrada V. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a sub analysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Infection. 2021 Aug;49(4):677-684. Doi: 10.1007/s15010-021-01587-9.

28.             Colucci M, Raisi A, Biering-Sørensen T, Gyenes M, Hodzic-Santor B, Manzoor S, Skaarup K, Morgridge J, Rauda skis A, Sarma S, Razak F, Verma A, Fralick M. Demographics, medication use, and admission characteristics of patients hospitalized with diabetes in Ontario, Canada: A retrospective cohort study. Plops One. 2024 Aug 29;19(8): e0307581. Doi: 10.1371/journal.pone.0307581.